Real-World Study of Molecular Typing and Targeted Treatment in Advanced Thyroid Cancer

What this Trial Is About

Researchers are studying the use of molecular typing in the treatment of advanced thyroid cancer through a real-world clinical study that includes both retrospective and prospective parts. The retrospective study looks back at patients treated from January 2020 to December 2023 in 24 hospitals, gathering data on treatment history, molecular test results, adverse reactions, and survival outcomes. The prospective study will enroll patients from January 2024 to April 2027 receiving precise treatments in the same hospitals. This study aims to understand how molecular typing can guide treatment in various types of advanced thyroid cancer, including differentiated, medullary, poorly differentiated, and anaplastic forms. Participants receive targeted drug treatments based on the type of gene mutations found in their cancer. These treatments include dabrafenib plus trametinib for BRAF V600E mutation, entrectinib or larotrectinib for NTRK mutation, pralsetinib or selpercatinib for RET fusion or mutation, anlotinib for medullary carcinoma without RET mutation, lenvatinib combined with anti-PD-1 antibody for patients without specific mutations or unable to afford precision therapy, and other targeted treatments based on identified targets. The study includes several patient groups defined by cancer type and suitability for radioiodine therapy. During the study, researchers will collect and analyze clinical data, molecular test results, medication regimens, and follow-up survival information up to about three years. Key outcomes measured include objective response rate, duration and time to response, disease control rate, progression-free survival, and overall survival. Safety and adverse reactions are also monitored. The study involves ongoing data collection and follow-up to assess how molecularly guided treatments affect advanced thyroid cancer management over time.

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer